Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
This study is currently recruiting participants.
Study NCT00077285 Information provided by National Cancer Institute (NCI)
First Received: February 10, 2004 Last Updated: July 7, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sarcoma
Additional conditions recognized in this trial
Rhabdomyosarcoma
More general conditions related to this trial
Myosarcoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Muscle Tissue
Interventions listed in this trial
filgrastim
carboplatin
cyclophosphamide
dexrazoxane hydrochloride
doxorubicin hydrochloride
etoposide
ifosfamide
irinotecan hydrochloride
vincristine sulfate
conventional surgery
radiation therapy
Additional drug interventions recognized in this trial
Camptothecin
Doxorubicin
Irinotecan
Razoxane
Vincristine
More general drug interventions related to this trial
Alkylating Agents
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Cardiovascular Agents
Chelating Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
